New Delhi: Pathology laboratory chain, Metropolis Healthcare ended the third quarter of fiscal year with a revenue of Rs 406 crore, up 26 per cent on year-on-yea (YoY) basis.
Ebitda for the quarter stood at Rs 95 crore, while net profit jumped 63 per cent YoY to Rs 51 crore.
In Q3, B2B revenue grew 35 per cent YoY, and revenue from direct to consumer offerings expanded 19 per cent from the year ago quarter.
Revenue per test (RPT) and revenue per patient (RPP) increased 11 per cent and 10 per cent YoY, respectively, driven by higher adoption of advanced diagnostics.
Patient and test volumes continued their positive trajectory, growing 14 per cent and 13 per cent YoY, respectively.
The company has completed the integration of its recent acquisitions and reported continued outperformance from Scientific Pathology (Agra), Dr. Ahuja’s Pathology & Imaging Center (Dehradun), and Dr. R. S. Patil’s Ambika Pathology Laboratory (Kolhapur).
“Our Q3 performance reflects how Metropolis is capturing these opportunities in Tier II and Tier III markets through a clear strategic focus and sustained investments in specialised capabilities,” said Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited.
